# IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

> **NCT06376526** · PHASE2 · RECRUITING · sponsor: **Dickran Kazandjian, MD** · enrollment: 28 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Linvoseltamab

## Key facts

- **NCT ID:** NCT06376526
- **Lead sponsor:** Dickran Kazandjian, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-21
- **Primary completion:** 2027-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06376526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06376526, "IMMUNOPLANT for Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06376526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*